These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31724039)

  • 1. Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes.
    Khan N; Tso K; Broussard J; Dziuba M
    Am J Health Syst Pharm; 2019 Nov; 76(23):1930-1933. PubMed ID: 31724039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Acidosis in Postsurgical Patient on Canagliflozin and Metformin: A Case Report.
    Darwish AM
    A A Pract; 2019 Apr; 12(7):221-222. PubMed ID: 30234515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
    Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
    Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fournier's Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications.
    Kasbawala K; Stamatiades GA; Majumdar SK
    Am J Case Rep; 2020 Jun; 21():e921536. PubMed ID: 32483108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
    Sugimoto K; Abe I; Minezaki M; Takashi Y; Ochi K; Fujii H; Ohishi H; Yamao Y; Kudo T; Ohe K; Abe M; Ohnishi Y; Shinagawa T; Mukoubara S; Kobayashi K
    Drug Discov Ther; 2019; 13(6):322-327. PubMed ID: 31956230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan.
    Goda M; Yamakura T; Sasaki K; Tajima T; Ueno M
    Curr Med Res Opin; 2018 Feb; 34(2):319-327. PubMed ID: 29025285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
    Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
    Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus.
    Elbeddini A; Gallinger J; Davey M; Brassard S; Gazarin M; Plourde F; Aly A
    Am J Case Rep; 2020 Feb; 21():e920115. PubMed ID: 32089542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    Seko Y; Sumida Y; Sasaki K; Itoh Y; Iijima H; Hashimoto T; Ishii S; Inagaki N
    J Gastroenterol; 2018 Jan; 53(1):140-151. PubMed ID: 28669071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study.
    Matsuba I; Kanamori A; Takihata M; Takai M; Maeda H; Kubota A; Iemitsu K; Umezawa S; Obana M; Kaneshiro M; Kawata T; Takuma T; Takeda H; Machimura H; Mokubo A; Motomiya T; Asakura T; Kikuchi T; Matsuzawa Y; Ito S; Miyakawa M; Terauchi Y; Tanaka Y
    Diabetes Technol Ther; 2020 Mar; 22(3):228-234. PubMed ID: 32013567
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
    Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Ways K; Desai M; Shaw W; Capuano G; Alba M; Jiang J; Vercruysse F; Meininger G; Matthews D;
    Diabetes Care; 2015 Mar; 38(3):403-11. PubMed ID: 25468945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.
    Rodbard HW; Peters AL; Slee A; Cao A; Traina SB; Alba M
    Diabetes Care; 2017 Feb; 40(2):171-180. PubMed ID: 27899497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
    Nandula SR; Kundu N; Awal HB; Brichacek B; Fakhri M; Aimalla N; Elzarki A; Amdur RL; Sen S
    Cardiovasc Diabetol; 2021 Feb; 20(1):44. PubMed ID: 33581737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
    Elmore LK; Baggett S; Kyle JA; Skelley JW
    Consult Pharm; 2014; 29(5):335-46. PubMed ID: 24849690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.